ESMO ADVANCED COURSE PROGRAMME

PERIOPERATIVE STRATEGIES IN LOCALIZED MALIGNANCIES
State of the art and future directions in lung cancer
Hong Kong SAR, China
20-21 April 2024

CO-CHAIRS
Rafal Dziadziuszko, Poland
Tony S. K. Mok, Hong Kong SAR, China
Fan Yang, China

SPEAKERS
Hisao Asamura, Japan
Rina Hui, Hong Kong SAR, China
Rainbow W. H. Lau, Hong Kong SAR, China
Natasha Leighl, Canada
Thanpanyan Baisamut (Reungwetwattana), Thailand
Witold Rzyman, Poland
Jonathan Spicer, Canada
Pan-Chyr Yang, Taiwan
Yi-Long Wu, China

LEARNING OBJECTIVES
- To update the importance of early lung detection in smokers and never-smokers
- To appreciate the implication of latest staging and molecular classification for early-stage lung cancer
- To learn the advances in surgical management of early-stage lung cancer
- To comprehend the role of neo-adjuvant and adjuvant therapy for patients with oncogene driven and non-oncogene driven resectable lung cancer

ACCREDITATION
The programme of this event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS
ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
09:00-09:10  Welcome and introduction
Rafal Dziadziszko, PL
Tony S. K. Mok, HKSAR CN
Fan Yang, CN

09:10-10:15  Session 1 – Screening, staging and molecular testing
(Chair: )
15’  Screening (Asia perspective)
Pan-Chyr Yang, TW

15’  Screening (EU perspective)
Witold Rzyman, PL

20’  Staging
Hisao Asamura, JP

15’  Discussion

10:15-10:45  Coffee break

10:45-12:00  Session 2 – Surgery
(Chair: )
20’  Current surgical approach to lung cancer: Segmantectomic vs lobectomy
Witold Rzyman, PL

20’  Resection of the marginally resectable lung cancer
Fan Yang, CN

20’  Advances in surgical techniques
Rainbow W. H. Lau, HKSAR CN

15’  Discussion

12:00-13:15  Session 3 – Neo-adjuvant, adjuvant and targeted therapies
(Chair: )
20’  Neo-adjuvant vs adjuvant (focusing on non-oncogene)
Jonathan Spicer, CA

20’  Do biomarkers and MRD matter? (PDL1, TMB, ...)
Tony S. K. Mok, HKSAR CN

20’  Molecular testing
Natasha Leighl, CA

15’  Discussion

13:15-14:15  Lunch
14:15-15:10  Session 4 – Early stage, oncogene
         (Chair: )
         20’  Early resectable lung cancer
              Yi-Long Wu, CN
         20’  Basic management of stage III
              Rafal Dziadzuiszko, PL
         15’  Discussion

15:10-15:40  Coffee break

15:40-17:00  Session 5 – Management Stage III non-oncogene driven lung cancer
         (Chair: )
         25’  Standard of radiation therapy
              Rafal Dziadzuiszko, PL
         20’  Should we give I/O to all Stage III patients after concurrent chemoradiation
              Rina Hui, HKSAR CN
         20’  The philosophy of multidisciplinary approach to management of Stage III disease
              Thanyanan Baisamut (Reungwetwattana), TH
         15’  Discussion and closure of the day

19:00  Networking dinner

Sunday, 21 April 2024

09:00-12:30  Workshop sessions
         25’  Introduction based on clinical cases presented by speakers
         35’  Discussion

Workshop 1  MTB: Multiple GGO and very early NSCLC
         60’  Speaker: Rainbow W. H. Lau, HKSAR, CN
              Moderator: Fan Yang, CN

Workshop 2  MTB: Stage II and Stage III EGFR mutation positive
         60’  Speaker: Natasha Leighl, CA
              Moderator: Tony S. K. Mok

11:00-11:30  Coffee break

Workshop 3  MTB: T4 / N2 disease
         60’  Speaker: Witold Rzyman, PL
              Moderator: Rafal Dziadziszko, PL

12:30-12:45  Synthesis and conclusion
         Rafal Dziadziszko, PL
         Tony S. K. Mok, HKSAR CN
         Fan Yang, CN

12:45-13:45  Lunch